NCT03890198View on ClinicalTrials.gov

A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

March 6, 2020

Study Completion Date

March 6, 2020

Conditions
Gastric CancerPancreatic Ductal Adenocarcinoma
Interventions
BIOLOGICAL

LCAR-C182A cells

Patients receive fludarabine (3×300 mg/ m\^2) and cyclophosphamide (3×30 mg/m\^2) IV on days -5 to-3, and then Patients receive CAR-T cells. PS：The specific dose of fludarabine and cyclophosphamide is adjusted according to the individual condition of the subject and the judgment of the investigator.

Trial Locations (1)

710004

The First Affiliated Hospital of Xian Jiaotong University, Xi’an

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER